search
Back to results

To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis

Primary Purpose

Cirrhosis

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Metaclopramide
Erythromycin
Placebo
Sponsored by
Institute of Liver and Biliary Sciences, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cirrhosis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

1. Patients who develop new onset feed intolerance to enteral nutrition

Exclusion Criteria:

  1. Any patient with current or past surgical abdomen including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery.
  2. Patients receiving enteral nutrition through gastrostomy or jejunostomy.
  3. Patients in whom, prokinetics are contraindicated or are allergic to the same.
  4. Patients who received prokinetic more than one day prior to the start of enteral feeding.
  5. Patients with uncontrolled sepsis with DIC.
  6. Requirement of two or more vasopressors.
  7. Organ failure requiring high inotropic support.
  8. Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart disease.
  9. History of traumatic brain injury, raised intracranial pressure, history of myasthenia gravis.
  10. Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism
  11. Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosis, amyloidosis).
  12. Known case of diabetes with diabetic gastroparesis
  13. Pregnancy
  14. Patients or concerned family member who fail to give consent for study enrollment
  15. Age less than 18 years and more than 70 years.

Sites / Locations

  • Institute of liver and Biliary Sciences

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Metaclopromide group

Erythromycin group

Placebo group

Arm Description

Outcomes

Primary Outcome Measures

Resolution of feed intolerance at 24 hours with improvement in 3 or more points and initiation of entral feeding.
Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension

Secondary Outcome Measures

Survival
Survival
Number of patients with Initiation of entral nutrition more than 50%. of recommended nutrition (Kcal/kg body weight/day).
Feed intolerance is also defined when entral nutrition provided < 20Kcal/kg body weight/day.
Number of patients with resolution of atleast 2 out of 5 symptoms in all the 3 groups.
Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension
Number of patients with resolution of sepsis, shock, organ failure in all the 3 groups.
Number of patients without Ventilatory support in all the 3 groups.
Number of patients without inotropic supports in all the 3 groups.

Full Information

First Posted
August 17, 2015
Last Updated
November 18, 2017
Sponsor
Institute of Liver and Biliary Sciences, India
search

1. Study Identification

Unique Protocol Identification Number
NCT02528760
Brief Title
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
Official Title
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
September 24, 2015 (Actual)
Primary Completion Date
August 31, 2017 (Actual)
Study Completion Date
August 31, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
All patients with chronic liver disease admitted in ICU (Intensive Care Unit) to be screened. Patients fulfilling criteria for feed intolerance to be included in the study. Patients to undergo routine biochemical and hematological testing including CBC, KFT, LFT, PT/INR, electrolytes baseline and daily along with ABG (Arterial Blood gas) analysis. Patients with ascites to be tested for presence or absence of SBP (Spontaneous Bacterial Peritonitis). Cultures to be sent as based on clinical parameter of the patient. All correctable causes for intra abdominal hypertension to be corrected including electrolyte imbalance, grade III ascites, intra abdominal infection. Symptoms- Absent bowel sounds (BS)= no BS detected by auscultation. Vomiting/regurgitation= any visible regurgitation of gastric contents; Diarrhoea= liquid stool > or =3 times/day; Bowel distension= suspected clinically and radiologically confirmed; Large gastric residual volume (GRV) of >or =500 ml/24 h on a single day or > 200ml at any time of the day. Per abdomen findings to be checked daily including presence of bowel sounds, tenderness, development of abdominal distension, abdominal girth monitoring and abdominal pressure monitoring. Patients who develop feed intolerance will be included. Feed intolerance to be defined as per study definition (3 out of 5 symptoms). Measurement of GRV (Gastric residual volume) to be done at 4 hourly interval. Methods for measuring GRV by either gravity drainage by connecting a gastric tube to a drainage bag for 10min or by manual aspiration of content using a 50ml syringe. Once feed intolerance develop than every 6 hourly intra abdominal pressure monitoring and abdominal girth monitoring to be done (24) Intra bladder pressure to be measured using Foleys manometer technique (25). Pressure measured in cm of water to be converted into mm of Hg. X ray abdomen supine to look for bowel distension, defined as more than 3 cm for small bowel and more than 5 cm in large bowel. Development of intra abdominal hypertension based on intra abdominal pressure. Patient to be stratified according to the grade of intra-abdominal hypertension. After correction of all correctable causes, if feed intolerance persists, then patient to be randomized by block randomization method into 3 arms, metaclopromide group, erythromycin group or placebo group. Daily assessment of bowel sounds, abdominal pressure, abdominal girth every 6 hourly and gastric residual volume to be noted every 4 hourly. Response of therapy to be assessed at 24 hours in each arm. Response to be assessed by resolution of feed intolerance or initiation of entral nutrition. Metoclopromide to be given 10mg iv 8 hourly. Erythromycin to be given 70mg iv 12 hourly (26). Placebo arm to receive normal saline in 10ml syring twice daily. After 24 hours of treatment if symptoms do not resolve than rescue treatment will be given to each arm which may include continuation of prokinetics, add on prokinetic, flatus tube insertion for bowel decompression, upgradation of antibiotics or search for any other cause, as per the patient response. Therapy to continue for a total duration of 72 hours. If there is no response at 72 hours, than study stops. If patient responds to given treatment, study to continue for a total duration of 7 days. Assessment to continue in each arm for a maximum period of 7 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metaclopromide group
Arm Type
Experimental
Arm Title
Erythromycin group
Arm Type
Experimental
Arm Title
Placebo group
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Metaclopramide
Intervention Description
23. Metoclopromide to be given 10mg iv 8 hourly
Intervention Type
Drug
Intervention Name(s)
Erythromycin
Intervention Description
Erythromycin to be given 70mg iv 12 hourly.
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Resolution of feed intolerance at 24 hours with improvement in 3 or more points and initiation of entral feeding.
Description
Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Survival
Time Frame
72 hours
Title
Survival
Time Frame
7 days
Title
Number of patients with Initiation of entral nutrition more than 50%. of recommended nutrition (Kcal/kg body weight/day).
Description
Feed intolerance is also defined when entral nutrition provided < 20Kcal/kg body weight/day.
Time Frame
72 hours
Title
Number of patients with resolution of atleast 2 out of 5 symptoms in all the 3 groups.
Description
Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension
Time Frame
72 hours
Title
Number of patients with resolution of sepsis, shock, organ failure in all the 3 groups.
Time Frame
7 days
Title
Number of patients without Ventilatory support in all the 3 groups.
Time Frame
7 days
Title
Number of patients without inotropic supports in all the 3 groups.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Patients who develop new onset feed intolerance to enteral nutrition Exclusion Criteria: Any patient with current or past surgical abdomen including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery. Patients receiving enteral nutrition through gastrostomy or jejunostomy. Patients in whom, prokinetics are contraindicated or are allergic to the same. Patients who received prokinetic more than one day prior to the start of enteral feeding. Patients with uncontrolled sepsis with DIC. Requirement of two or more vasopressors. Organ failure requiring high inotropic support. Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart disease. History of traumatic brain injury, raised intracranial pressure, history of myasthenia gravis. Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosis, amyloidosis). Known case of diabetes with diabetic gastroparesis Pregnancy Patients or concerned family member who fail to give consent for study enrollment Age less than 18 years and more than 70 years.
Facility Information:
Facility Name
Institute of liver and Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India

12. IPD Sharing Statement

Learn more about this trial

To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis

We'll reach out to this number within 24 hrs